NEW YORK, Feb. 2, 2011 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:
Global Coronary Stents Industry
http://www.reportlinker.com/p098248/Global-Coronary-Stents-Industry.html
This report analyzes the worldwide markets for Coronary Stents in US$ Million and Thousand Units by the following product segments: Bare Metal Stents, and Drug Eluting Stents. The report provides separate comprehensive analytics for the US, Japan, Europe, Asia Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A six-year historic analysis is also provided for these markets. The report profiles 52 companies including many key and niche players such as Angiotech Pharmaceuticals, Abbott Vascular, Biosensors International, Boston Scientific Corp., Cordis Corporation, Cook Group, Inc., Medtronic, Inc., Medtronic Vascular, Inc., and OrbusNeich. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
CORONARY STENTS MCP-1148
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Data Interpretation & Reporting Level 3
Quantitative Techniques & Analytics 3
Product Definitions and Scope of Study 3
Bare Metal Stents 3
Drug Eluting Stents 4
2. GLOBAL MARKET OVERVIEW 5
Growth Revives as Drug Eluting Stents Bounce Back 5
What's Next on Cards in Coronary Stent Market? 5
Market Snapshots 6
Current and Future Analysis 7
Drug Eluting Stents Steal the Show 7
3. MARKET TRENDS AND ISSUES 8
Drug Eluting Stent System - Safety Concerns 8
Declining Prices - A Major Concern 8
Restenosis - the Real Growth Driver 8
Table 1: Growth in Angioplasty Procedures Vs Stent
Penetration Worldwide: (1997-2006) (includes corresponding
Graph/Chart) 9
Small Vessels - A Major Cause of Restenosis 9
Aging Population Propels Coronary Stent Market 9
Next Generation Stents - A Boon for Treating Coronary Diseases 9
Direct Stenting Systems Spur Growth 10
Drug Choice Impacts Market Entry 10
Threats to Coronary Stents - Alternative Therapies/Devices 10
Cell Transplantation - A Major Threat to Coronary Stents 11
Coronary Stents Market Challenged by Drug Therapy 11
4. COMPETITIVE ANALYSIS 12
Coronary Stents - Leading Players 12
Table 2: Leading Players in the Global Coronary Stents Market
(2008) - Percentage Breakdown by Revenues for Boston
Scientific, Johnson & Johnson, Medtronic, and Others
(includes corresponding Graph/Chart) 12
Bare Metal Stents - Leading Players 12
Table 3: Leading Players in the Global Bare Metal Stents
Market (2007) - Percentage Breakdown by Revenues for Abbott,
Johnson & Johnson, Boston Scientific, Medtronic, and Others
(includes corresponding Graph/Chart) 12
Drug-Eluting Stents - Leading Players 13
Table 4: Leading Players in the Global Drug-Eluting Stent
Market (2008) - Percentage Breakdown by Revenues for Boston
Scientific, Johnson & Johnson, and Others (includes
corresponding Graph/Chart) 13
Comparative Analysis of the Leading Players 13
5. CORONARY DISEASE - A PERSPECTIVE 15
Factors Responsible for Coronary Diseases 15
Controllable Risk Factors 15
High Blood Cholesterol 15
Sedentary Life Style and Habits 15
Smoking Habits 15
High Blood Pressure 16
Uncontrollable Risk Factors 16
Age 16
Heredity 16
Gender 16
Causative Risk Factors 16
Stress and Anger 16
Obesity 17
Diabetes 17
Symptoms of Coronary Artery Disease 17
Diagnosis 17
Treatment 18
Drug Supported Treatments 18
Invasive Treatments 18
Bypass Surgery 18
Percutaneous Transluminal Coronary Angioplasty (Balloon
Angioplasty) 18
Natural Therapy 19
Coronary Angioplasty Suitable for Acute Myocardial Infarction 19
Advancements in Coronary Disease Treatment Modalities 19
University of Virginia's Microbe Solution for Post Surgical
Complications 19
Radiation for Re-clogged Arteries Show Promise 20
Radioactive Coronary Stents Promise Bright Future 20
6. CORONARY STENTS - PRODUCT OVERVIEW 21
Introduction 21
Evolution of Coronary Stents 21
Applications of Coronary Stents 21
Stent Deployment 22
Key Stent Delivery Platforms by Select Company 23
Coronary Stent Designs 23
Key Factors Determining Coronary Stent Performance 23
Delivery Convenience 23
Efficient Scaffolding 23
Radiopacity (Visibility) 24
Optimum Flexibility 24
Shape Conformability 24
Material for Coronary Stent 24
Risk Associated with Stenting 24
Improper Stent Implantation Likely Cause for In-Stent Restenosis 25
Precautions 26
Direct Coronary Stenting - Creating an Enliven 26
Limitations 26
Regulatory Approvals Wooing Stent Market 27
A Peek into Regulatory Approvals for Coronary Stents 27
7. PRODUCT SEGMENTS 31
Bare Metal Stents 31
Major Bare Metal Stents by Company 31
Drug-Eluting Stents 31
DE Stents Overshadow Intravascular Brachytherapy Interventions 32
Major Drug-Eluting Stents by Company 32
Drugs for Coating DESs 32
Cytotoxic or Cytostatic Drug - the Debate Continues 33
Dosing and Deliverability Crucial for DES 33
Polymer Coatings for Effective Dosing and Deliverability 33
Drugs Used for DES by Major Competitors in the Stent Market 33
Leading Coronary Stent Brands 34
Cypher 34
Structure and Delivery Mechanism 34
Taxus 35
Structure and Delivery Mechanism 35
8. RESEARCH AND DEVELOPMENT 36
Extensive R&D Underway in Global Drug-Eluting Stents Market 36
At the Labs 36
Other Products Under Trials - A Recent Past Perspective 36
OMT Developing R-stent 36
Reva Developing Stainless Steel Bare-Metal Stent 36
D & P Corp Developing Bovine Pericardium- Covered Stent 36
Advanced Bio Synthesizing Porous Drug-Eluting Stents 37
Lombard Medical Developing PEP Coatings 37
Shiga Develops Biodegradable Drug-Eluting Stent 37
9. PRODUCT INTRODUCTIONS 38
Boston Scientific Launches Taxus Element Stent System in
European Union 38
Boston Scientific Introduces Taxus Eluting Stent System 38
Boston Scientific Unveils TAXUS Liberte Paclitaxel Eluting
Stent System in Japan 38
Alvimedica Launches Coracto Drug-Eluting Stent in Europe 38
Abbott Labs to Launch XIENCE V in China 39
Existent Introduces Premier Coronary Stent System 39
Medtronic to Unveil Balloon Catheter Systems and Coronary Stents 39
NanoInterventions Launches Mouse Stent Model 39
InspireMD - MGuard™ Coronary Stent Launched in Italy 39
CeloNova BioSciences Launches CATANIA™ Coronary Stent with
NanoThin Polyzene®-F 40
Angiotech Launches Cook Medical's Drug Eluting Zilver® PTX™
Stent in New Zealand 40
Boston Scientific Launches Its Own Version of XIENCE™V Drug-
Eluting Coronary Stent in Europe 40
Sorin Debuts Janus and CHRONO™ 41
Guidant's New Coronary Stent System Enters Japanese Realm 41
Boston Gears Up for Market Expansion of TAXUS Liberte 41
Trimax - A New Coronary Stent From Abbott 41
JNJ Ramps Up Production of Cypher 42
10. RECENT INDUSTRY ACTIVITY 43
Boston Scientific Expands PROMUS® Everolimus-Eluting Coronary
Stent System 43
Boston Scientific Receives TGS Approval from Australia 43
Svelte Medical Systems Commences Clinical Trial of SOAW
Delivery System 43
Abbott Receives Japan's MHLW Approval for Xience V 43
Opto Circuits Receives Mark Approval from Communite European 43
Abbott Receives Health Canada Approval for XIENCE V® Stent System 44
Medtronic Secures Japan's MHLW Approval for Endeavor® Drug
Eluting Stent 44
Boston Scientific Takes Over Labcoat 44
Micell and Maxcor Sign Strategic Agreement 44
Cordis Receives FDA Approval for Variant of Cypher Sirolimus-
Eluting Coronary Stent 44
Boston Scientific Obtains CE Mark Approval for Promus Element
Everolimus-Eluting Coronary Stent System 44
Cypher Select® Plus Sirolimus-eluting Coronary Stent Gains CE
Mark for Treatment in Diabetic Patients 45
Atrium Medical Obtains CE Mark for CinatraTM 45
Medtronic Secures CE Mark Approval for Endeavor Drug-Eluting
Stent for Use in Treatment of ACS 45
CorNova® Obtains CE mark approval for Valecor Platinum
Coronary Stent System 45
Cook Medical Receives CE Mark Approval and Launches Zilver®
PTX® Drug-Eluting Peripheral Stent 46
Disa Receives CE Approval for Coronary Stent 46
Datascope Acquires Peripheral Stent Business of Sorin Group 46
Boston Scientific Receives FDA approval for TAXUS® Liberte®
Drug-Eluting STENT 46
Abbott Labs Receives FDA Approval for Xience V 47
Bard to Purchase Assets of LifeStent Product Portfolio 47
Medtronic Receives the US FDA Approval to Use Endeavor® Stent 47
Medtronic Inc. Receives Approval for its Drug-Eluting Stent,
"Endeavor" In Canada 47
Boston Scientific to Market TAXUS® Liberte® Stent System in
Canada 48
Abbott Applies for Approval of XIENCE™ V in Japan 48
Medinol Achieves CE Mark Approval for Presillion™ Cobalt
Chromium Coronary Stent System 48
Iberhospitex Receives Spanish Approval to Sell Palau Pharma's
"Active" Coronary Stent 48
Clearstream's Intrepide Drug Eluting Stent of Clearstream
Receives CE mark approval 49
Terumo Introduces Its Drug-Eluting Stent in Germany and Marks
Its European Entry 49
Tryton Medical's Side-Branch Stent Achieves CE Mark Approval 49
CV Therapeutics Offers its Stent Coating Technology to
Medlogics Device Corporation 49
Abbott's 2.25mm-Sized XIENCE™ V Drug Eluting Stent receives CE
Mark of Approval 50
Biosensors Receives CE Mark Approval for BioMatrix® Stent System 50
Nfocus Neuromedical's CardioVasc™ Stent-Graft and Delivery
System Receives CE Mark Approval 50
11. STRATEGIC CORPORATE DEVELOPMENTS IN THE RECENT PAST - A
PERSPECTIVE BUILDER 51
Cook Medical's Zilver Stent Receives Approval for Vascular Use
In Canada 51
Boston Scientific to Market TAXUS® EXPRESS2 Stent System in Japan 51
CE Mark Granted for the Use of Drug-eluting Stent, TAXUS®
Liberte™ in Diabetic Patients 51
Boston Scientific's TAXUS® Liberte™ Long Stent Receives CE
Mark Approval 51
Boston Joins Forces with Guidant 52
Avantec Licenses Blue Membranes' Technology for DES 52
FDA Nods for Usage of CYPHER® in Overlapping Stenting 52
Guidant's XIENCE™ V Gets CE Marked 52
EuroCor Receives Definitive CE Mark Approval for Taxcor 52
BIOTRONIK Ties Up with Novartis 53
BIOTRONIK Collaborates with Micrus 53
CYPHER Select™ PLUS Gets CE Nod 53
Medtronic's Micro-Driver Bags FDA Approval 53
Conor Wins CE Mark Approval for CoStar™ 53
Relisys Collaborates with Blue Membranes 54
OCIL Steps Into the German Sphere by Acquiring EuroCor 54
Boston Purchases Advanced Stent Technologies 54
Neich Medical Acquires Orbus Medical 54
MIV Therapeutics To Purchase Assets of Sahajanand 54
Conor's Unistar Becomes CE Approved 55
CE Clears DISA's Small-Vessel Heart Stent 55
Boston's TAXUS Express2 for Larger Vessels Gets Lucrative
Approvals 55
Boston Inaugurates R&D Center 55
12. FOCUS ON SELECT PLAYERS 56
Angiotech Pharmaceuticals (Canada) 56
Abbott Vascular (USA) 56
Biosensors International (USA) 56
Boston Scientific Corp. (USA) 57
Cordis Corporation (JNJ) - (USA) 57
Cook Group, Inc. (USA) 57
Medtronic, Inc. (USA) 58
Medtronic Cardiovascular, Inc. (USA) 58
OrbusNeich (USA) 58
13. GLOBAL MARKET PERSPECTIVE 59
Table 5: World Recent Past, Current & Future Analysis for
Coronary Stents By Geographic Region - US, Japan, Europe,
Asia-Pacific (Excluding Japan) and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for
years 2007 through 2015 (includes corresponding Graph/Chart) 59
Table 6: World Recent Past, Current & Future Analysis for
Coronary Stents by Geographic Region - US, Japan, Europe,
Asia-Pacific (Excluding Japan) and Rest of World Markets
Independently Analyzed with Annual Sales in Thousand Units for
years 2007 through 2015 (includes corresponding Graph/Chart) 60
Table 7: World Historic Review for Coronary Stents by
Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding
Japan) and Rest of World Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2001 through 2006
(includes corresponding Graph/Chart) 61
Table 8: World Historic Review for Coronary Stents by
Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding
Japan) and Rest of World Markets Independently Analyzed with
Annual Sales in Thousand Units for Years 2001 through 2006
(includes corresponding Graph/Chart) 62
Table 9: World 11-Year Perspective for Coronary Stents by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of
World Markets for Years 2005, 2010 & 2015 (includes
corresponding Graph/Chart) 63
Table 10: World 11-Year Perspective for Coronary Stents by
Geographic Region - Percentage Breakdown of Unit Sales for US,
Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of
World Markets for Years 2005, 2010 & 2015 (includes
corresponding Graph/Chart) 64
Table 11: World Recent Past, Current & Future Analysis for
Bare Metal Stents by Geographic Region - US, Japan, Europe,
Asia - Pacific (Excluding Japan) and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for
years 2007 through 2015 (includes corresponding Graph/Chart) 65
Table 12: World Recent Past, Current & Future Analysis for
Bare Metal Stents by Geographic Region - US, Japan, Europe,
Asia - Pacific (Excluding Japan) and Rest of World Markets
Independently Analyzed with Annual Sales in Thousand Units for
years 2007 through 2015 (includes corresponding Graph/Chart) 66
Table 13: World Historic Review for Bare Metal Stents By
Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding
Japan) and Rest of World Markets Independently Analyzed with
Annual Sale sin US$ Million for Years 2001 through 2006
(includes corresponding Graph/Chart) 67
Table 14: World Historic Review for Bare Metal Stents By
Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding
Japan) and Rest of World Markets Independently Analyzed with
Annual Sales in Thousand Units for Years 2001 through 2006
(includes corresponding Graph/Chart) 68
Table 15: World 11-Year Perspective for Bare Metal Stents by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of
World Markets for Years 2005, 2010 & 2015 (includes
corresponding Graph/Chart) 69
Table 16: World 11-Year Perspective for Bare Metal Stents by
Geographic Region - Percentage Breakdown of Unit Sales for US,
Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of
World Markets for Years 2005, 2010 & 2015 (includes
corresponding Graph/Chart) 70
Table 17: World Recent Past, Current & Future Analysis for
Drug Eluting Stents by Geographic Region - US, Japan, Europe,
Asia - Pacific (Excluding Japan), and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2007 through 2015 (includes corresponding Graph/Chart) 71
Table 18: World Recent Past, Current & Future Analysis for
Drug Eluting Stents by Geographic Region - US, Japan, Europe,
Asia - Pacific (Excluding Japan), and Rest of World Markets
Independently Analyzed with Annual Sales in Thousand Units for
Years 2007 through 2015 (includes corresponding Graph/Chart) 72
Table 19: World Historic Review for Drug Eluting Stents by
Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding
Japan) and Rest of World Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2001 through 2006
(includes corresponding Graph/Chart) 73
Table 20: World Historic Review for Drug Eluting Stents by
Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding
Japan) and Rest of World Markets Independently Analyzed with
Annual Sales in Thousand Units for Years 2001 through 2006
(includes corresponding Graph/Chart) 74
Table 21: World 11-Year Perspective for Drug Eluting Stents by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of
World Markets for Years 2005, 2010 & 2015 (includes
corresponding Graph/Chart) 75
Table 22: World 11-Year Perspective for Drug Eluting Stents by
Geographic Region - Percentage Breakdown of Unit Sales for US,
Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of
World Markets for Years 2005, 2010 & 2015 (includes
corresponding Graph/Chart) 76
14. UNITED STATES 77
A. Market Analysis 77
Largest Market Worldwide 77
Coronary Artery Disease - A US Perspective 77
Baby Boomers Boost Coronary Stent Market 77
Revival in the DES Market 77
Reimbursement System 78
National Average Medicare Payment For DRGS 78
Competitive Scenario 79
Leading Players 79
Coronary Stents - Boston Scientific and JNJ Battle for
Dominance 79
Table 23: Leading Players in the US Coronary Stents
Market (2006) - Percentage Breakdown by Revenues for
Boston Scientific, Johnson & Johnson and Others (includes
corresponding Graph/Chart) 79
Drug Eluting Stents - Competition in the Brewing 79
Table 24: Leading Players in the US Drug-Eluting Stents
Market (2007) - Percentage Breakdown by Revenues for
Boston Scientific, and Johnson & Johnson 79
Regulatory Environment 79
B. Market Analytics 80
Table 25: US Recent Past, Current & Future Analysis for
Coronary Stents by Product Segment - Bare Metal and Drug
Eluting Stent Markets Independently Analyzed with Annual
Sales in US$ Million for years 2007 through 2015 (includes
corresponding Graph/Chart) 80
Table 26: US Recent Past, Current & Future Analysis for
Coronary Stents by Product Segment - Bare Metal and Drug
Eluting Stent Markets Independently Analyzed with Annual
Sales in Thousand Units for years 2007 through 2015
(includes corresponding Graph/Chart) 81
Table 27: US Historic Review for Coronary Stents by Product
Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in US$ Million for
years 2001 through 2006 (includes corresponding Graph/Chart) 81
Table 28: US Historic Review for Coronary Stents by Product
Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in Thousand Units
for years 2001 through 2006 (includes corresponding
Graph/Chart) 82
Table 29: US 11-Year Perspective for Coronary Stents by
Product Segment - Percentage Breakdown of Dollar Sales for
Bare Metal Stents and Drug Eluting Stents Markets for years
2005, 2010 & 2015 82
Table 30: US 11-Year Perspective for Coronary Stents by
Product Segment - Percentage Breakdown of Unit Sales for
Bare Metal Stents and Drug Eluting Stents Markets for years
2005, 2010 & 2015 82
15. JAPAN 83
A.Market Analysis 83
Prospects Weighed down by Regulatory Entanglements 83
Japanese Coronary Stents Command Higher Prices 83
Table 31: Coronary Stent Pricing (2008): Comparative
Analysis of Prices in Japan, US, Europe and Global Average
(includes corresponding Graph/Chart) 83
Competitive Landscape 84
Table 32: Leading Players in the Japanese Coronary Stent
Market ( 2006) - Percentage Breakdown by Value Sales for
Johnson & Johnson, Medtronic, Boston Scientific, and Others
(includes corresponding Graph/Chart) 84
Table 33: Leading Players in the Japanese Bare Metal Stent
Market (2006) - Percentage Breakdown by Value Sales for
Guidant, Medtronic, Boston Scientific, JNJ and Others
(includes corresponding Graph/Chart) 84
Table 34: Leading Players in Japanese Drug-Eluting Stent
Market (2007) - Percentage Breakdown by Revenues for
Johnson & Johnson and Boston Scientific 85
B.Market Analytics 85
Table 35: Japanese Recent Past, Current & Future Analysis
for Coronary Stents by Product Segment - Bare Metal and Drug
Eluting Stent Markets Independently Analyzed with Annual
Sales in US$ Million for years 2007 through 2015 (includes
corresponding Graph/Chart) 85
Table 36: Japanese Recent Past, Current & Future Analysis
for Coronary Stents by Product Segment - Bare Metal and Drug
Eluting Stent Markets Independently Analyzed with Annual
Sales in Thousand Units for years 2007 through 2015
(includes corresponding Graph/Chart) 86
Table 37: Japanese Historic Review for Coronary Stents by
Product Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in US$ Million for
years 2001 through 2006 (includes corresponding Graph/Chart) 86
Table 38: Japanese Historic Review for Coronary Stents by
Product Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in Thousand Units
for years 2001 through 2006 (includes corresponding
Graph/Chart) 87
Table 39: Japanese 11-Year Perspective for Coronary Stents
by Product Segment - Percentage Breakdown of Dollar Sales
for Bare Metal Stents and Drug Eluting Stents Markets for
years 2005, 2010 & 2015 87
Table 40: Japanese 11-Year Perspective for Coronary Stents
by Product Segment - Percentage Breakdown of Unit Sales for
Bare Metal Stents and Drug Eluting Stents Markets for years
2005, 2010 & 2015 87
16. EUROPE 88
A.Market Analysis 88
Cardiovascular Disease in Europe - A Perspective 88
Growth Bar Too Low 88
Table 41: Price of Stents in Europe & the United States for
Years 2003-2006: A Comparison (includes corresponding
Graph/Chart) 89
Two-Speed Europe 89
Stent Market's Merger Mania 89
Dampeners to Rapid Adoption of DES in Europe 90
Competitive Scenario 90
Table 42: Leading Players in the European Bare Metal Stent
Market ( 2005 & 2006) - Percentage Breakdown by Value Sales
for Guidant, Medtronic,Boston Scientific, Johnson &
Johnson, and Others (includes corresponding Graph/Chart) 90
Table 43: Leading Players in the European Drug-Eluting
Stent Market (2005 & 2006) - Percentage Breakdown by Value
Sales for Johnson & Johnson, Boston Scientific, Medtronic,
and Others (includes corresponding Graph/Chart) 91
B.Market Analytics 92
Table 44: European Recent Past, Current & Future Analysis
for Coronary Stents by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets
Independently Analyzed with Annual Sales in US$ Million for
years 2007 through 2015 (includes corresponding Graph/Chart) 92
Table 45: European Recent Past, Current & Future Analysis
for Coronary Stents by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets
Independently Analyzed with Annual Sales in Thousand Units
for years2007 through 2015 (includes corresponding
Graph/Chart) 93
Table 46: European Historic Review for Coronary Stents by
Geographic Region - France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets Independently Analyzed
with Annual Sales in US$ Million for years 2001 through 2006
(includes corresponding Graph/Chart) 94
Table 47: European Historic Review for Coronary Stents by
Geographic Region - France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets Independently Analyzed
with Annual Sales in Thousand Units for years 2001 through
2006 (includes corresponding Graph/Chart) 95
Table 48: European 11-Year Perspective for Coronary Stents
by Geographic Region - Percentage Breakdown of Dollar Sales
for France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets for Years 2005, 2010 & 2015 (includes
corresponding Graph/Chart) 96
Table 49: European 11-Year Perspective for Coronary Stents
by Geographic Region - Percentage Breakdown of Unit Sales
for France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets for Years 2005, 2010 & 2015 (includes
corresponding Graph/Chart) 97
Table 50: European Recent Past, Current & Future Analysis
for Coronary Stents by Product Segment - Bare Metal and Drug
Eluting Stents Markets Independently Analyzed with Annual
sales in US$ Million for years 2007 through 2015 (includes
corresponding Graph/Chart) 98
Table 51: European Recent Past, Current & Future Analysis
for Coronary Stents by Product Segment - Bare Metal and Drug
Eluting Stents Markets Independently Analyzed with Annual
sales in Thousand Units for years 2007 through 2015
(includes corresponding Graph/Chart) 99
Table 52: European Historic Review for Coronary Stents by
Product Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in US$ Million for
years 2001 through 2006 (includes corresponding Graph/Chart) 100
Table 53: European Historic Review for Coronary Stents by
Product Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in Thousand Units
for years 2001 through 2006 (includes corresponding
Graph/Chart) 100
Table 54: European 11-Year Perspective for Coronary Stents
by Product Segment - Percentage Breakdown of Dollar Sales
for Bare Metal Stents and Drug Eluting Stents Markets for
years 2005, 2010 & 2015 101
Table 55: European 11-Year Perspective for Coronary Stents
by Product Segment - Percentage Breakdown of Unit Sales for
Bare Metal Stents and Drug Eluting Stents Markets for years
2005, 2010 & 2015 101
16a.FRANCE 102
Market Analysis 102
Table 56: French Recent Past, Current & Future Analysis for
Coronary Stents by Product Segment - Bare Metal Stent and
Drug Eluting Stent Markets Independently Analyzed with
Annual Sales in US$ Million for years 2007 through 2015
(includes corresponding Graph/Chart) 102
Table 57: French Recent Past, Current & Future Analysis for
Coronary Stents by Product Segment - Bare Metal Stent and
Drug Eluting Stent Markets Independently Analyzed with
Annual Sales in Thousand Units for years 2007 through 2015
(includes corresponding Graph/Chart) 103
Table 58: French Historic Review for Coronary Stents by
Product Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in US$ Million for
years 2001 through 2006 (includes corresponding Graph/Chart) 103
Table 59: French Historic Review for Coronary Stents by
Product Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in Thousand Units
for years 2001 through 2006 (includes corresponding
Graph/Chart) 104
Table 60: French 11-Year Perspective for Coronary Stents by
Product Segment - Percentage Breakdown of Dollar Sales for
Bare Metal Stents and Drug Eluting Stents Markets for years
2005, 2010 & 2015 104
Table 61: French 11-Year Perspective for Coronary Stents by
Product Segment - Percentage Breakdown of Unit Sales for
Bare Metal Stents and Drug Eluting Stents Markets for years
2005, 2010 & 2015 104
16b.GERMANY 105
Market Analysis 105
Table 62: German Recent Past, Current & Future Analysis for
Coronary Stents by Product Segment - Bare Metal Stent and
Drug Eluting Stent Markets Independently Analyzed with
Annual Sales in US$ Million for years 2007 through 2015
(includes corresponding Graph/Chart) 105
Table 63: German Recent Past, Current & Future Analysis for
Coronary Stents by Product Segment - Bare Metal Stent and
Drug Eluting Stent Markets Independently Analyzed with
Annual Sales in Thousand Units for years 2007 through 2015
(includes corresponding Graph/Chart) 106
Table 64: German Historic Review for Coronary Stents by
Product Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in US$ Million for
years 2001 through 2006 (includes corresponding Graph/Chart) 106
Table 65: German Historic Review for Coronary Stents by
Product Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in Thousand Units
for years 2001 through 2006 (includes corresponding
Graph/Chart) 107
Table 66: German 11-Year Perspective for Coronary Stents by
Product Segment - Percentage Breakdown of Dollar Sales for
Bare Metal Stents and Drug Eluting Stents Markets for years
2005, 2010 & 2015 107
Table 67: German 11-Year Perspective for Coronary Stents by
Product Segment - Percentage Breakdown of Unit Sales for
Bare Metal Stents and Drug Eluting Stents Markets for years
2005, 2010 & 2015 107
16c.ITALY 108
Market Analysis 108
Table 68: Italian Recent Past, Current & Future Analysis for
Coronary Stents by Product Segment - Bare Metal Stent and
Drug Eluting Stent Markets Independently Analyzed with
Annual Sales in US$ Million for years 2007 through 2015
(includes corresponding Graph/Chart) 108
Table 69: Italian Recent Past, Current & Future Analysis for
Coronary Stents by Product Segment - Bare Metal Stent and
Drug Eluting Stent Markets Independently Analyzed with
Annual Sales in Thousand Units for years 2007 through 2015
(includes corresponding Graph/Chart) 109
Table 70: Italian Historic Review for Coronary Stents by
Product Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in US$ Million for
years 2001 through 2006 (includes corresponding Graph/Chart) 109
Table 71: Italian Historic Review for Coronary Stents by
Product Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in Thousand Units
for years 2001 through 2006 (includes corresponding
Graph/Chart) 110
Table 72: Italian 11-Year Perspective for Coronary Stents by
Product Segment - Percentage Breakdown of Dollar Sales for
Bare Metal Stents and Drug Eluting Stents Markets for years
2005, 2010 & 2015 110
Table 73: Italian 11-Year Perspective for Coronary Stents by
Product Segment - Percentage Breakdown of Unit Sales for
Bare Metal Stents and Drug Eluting Stents Markets for years
2005, 2010 & 2015 110
16d.UNITED KINGDOM 111
Market Analysis 111
Table 74: UK Recent Past, Current & Future Analysis for
Coronary Stents by Product Segment - Bare Metal Stent and
Drug Eluting Stent Markets Independently Analyzed with
Annual Sales in US$ Million for years 2007 through 2015
(includes corresponding Graph/Chart) 111
Table 75: UK Recent Past, Current & Future Analysis for
Coronary Stents by Product Segment - Bare Metal Stent and
Drug Eluting Stent Markets Independently Analyzed with
Annual Sales in Thousand Units for years 2007 through 2015
(includes corresponding Graph/Chart) 112
Table 76: UK Historic Review for Coronary Stents by Product
Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in US$ Million for
years 2001 through 2006 (includes corresponding Graph/Chart) 112
Table 77: UK Historic Review for Coronary Stents by Product
Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in Thousand Units
for years 2001 through 2006 (includes corresponding
Graph/Chart) 113
Table 78: UK 11-Year Perspective for Coronary Stents by
Product Segment - Percentage Breakdown of Dollar Sales for
Bare Metal Stents and Drug Eluting Stents Markets for years
2005, 2010 & 2015 113
Table 79: UK 11-Year Perspective for Coronary Stents by
Product Segment - Percentage Breakdown of Unit Sales for
Bare Metal Stents and Drug Eluting Stents Markets for years
2005, 2010 & 2015 113
16e.SPAIN 114
Market Analysis 114
Table 80: Spanish Recent Past, Current & Future Analysis for
Coronary Stents by Product Segment - Bare Metal Stent and
Drug Eluting Stent Markets Independently Analyzed with
Annual Sales in US$ Million for years 2007 through 2015
(includes corresponding Graph/Chart) 114
Table 81: Spanish Recent Past, Current & Future Analysis for
Coronary Stents by Product Segment - Bare Metal Stent and
Drug Eluting Stent Markets Independently Analyzed with
Annual Sales in Thousand Units for years 2007 through 2015
(includes corresponding Graph/Chart) 115
Table 82: Spanish Historic Review for Coronary Stents by
Product Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in US$ Million for
years 2001 through 2006 (includes corresponding Graph/Chart) 115
Table 83: Spanish Historic Review for Coronary Stents by
Product Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in Thousand Units
for years 2001 through 2006 (includes corresponding
Graph/Chart) 116
Table 84: Spanish 11-Year Perspective for Coronary Stents by
Product Segment - Percentage Breakdown of Dollar Sales for
Bare Metal Stents and Drug Eluting Stents Markets for years
2005, 2010 & 2015 116
Table 85: Spanish 11-Year Perspective for Coronary Stents by
Product Segment - Percentage Breakdown of Unit Sales for
Bare Metal Stents and Drug Eluting Stents Markets for years
2005, 2010 & 2015 116
16f.RUSSIA 117
Market Analysis 117
Table 86: Russian Recent Past, Current & Future Analysis for
Coronary Stents by Product Segment - Bare Metal Stent and
Drug Eluting Stent Markets Independently Analyzed with
Annual Sales in US$ Million for years 2007 through 2015
(includes corresponding Graph/Chart) 117
Table 87: Russian Recent Past, Current & Future Analysis for
Coronary Stents by Product Segment - Bare Metal Stent and
Drug Eluting Stent Markets Independently Analyzed with
Annual Sales in Thousand Units for years 2007 through 2015
(includes corresponding Graph/Chart) 118
Table 88: Russian Historic Review for Coronary Stents by
Product Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in US$ Million for
years 2001 through 2006 (includes corresponding Graph/Chart) 118
Table 89: Russian Historic Review for Coronary Stents by
Product Segment - Bare Metal and Drug Eluting Stent Markets
Independently Analyzed with Annual Sales in Thousand Units
for years 2001 through 2006 (includes corresponding
Graph/Chart) 119
Table 90: Russian 11-Year Perspective for Coronary Stents by
Product Segment - Percentage Breakdown of Dollar Sales for
Bare Metal Stents and Drug Eluting StentsMarkets for years
2005, 2010 & 2015 119
Table 91: Russian 11-Year Perspective for Coronary Stents by
Product Segment - Percentage Breakdown of Unit Sales for
Bare Metal Stents and Drug Eluting Stents Markets for years
2005, 2010 & 2015 119
16g.REST OF EUROPE 120
Market Analysis 120
Table 92: Rest of Europe Recent Past, Current & Future
Analysis for Coronary Stents by Product Segment - Bare Metal
Stent and Drug Eluting Stent Markets Independently Analyzed
with Annual Sales in US$ Million for years 2007 through 2015
(includes corresponding Graph/Chart) 120
Table 93: Rest of Europe Recent Past, Current & Future
Analysis for Coronary Stents by Product Segment - Bare Metal
Stent and Drug Eluting Stent Markets Independently Analyzed
with Annual Sales in Thousand Units for years 2007 through
2015 (includes corresponding Graph/Chart) 121
Table 94: Rest of Europe Historic Review for Coronary Stents
by Product Segment - Bare Metal and Drug Eluting Stent
Markets Independently Analyzed with Annual Sales in US$
Million for years 2001 through 2006 (includes corresponding
Graph/Chart) 121
Table 95: Rest of Europe Historic Review for Coronary Stents
by Product Segment - Bare Metal and Drug Eluting Stent
Markets Independently Analyzed with Annual Sales in Thousand
Units for years 2001 through 2006 (includes corresponding
Graph/Chart) 122
Table 96: Rest of Europe 11-Year Perspective for Coronary
Stents by Product Segment - Percentage Breakdown of Dollar
Sales for Bare Metal Stents and Drug Eluting Stents Markets
for years 2005, 2010 & 2015 122
Table 97: Rest of Europe 11-Year Perspective for Coronary
Stents by Product Segment - Percentage Breakdown of Unit
Sales for Bare Metal Stents and Drug Eluting Stents Markets
for years 2005, 2010 & 2015 123
17. ASIA-PACIFIC 124
A.Market Analysis 124
China - Healthcare Reforms to Propel DES Market 124
Coronary Stent Market in a Bubble Zone Now 124
Regional Players and their DES Development Efforts 124
Cost Focus Helps Stent Makers Win the Market Stunt 125
B.Market Analytics 125
Table 98: Asia-Pacific Recent Past, Current & Future
Analysis for Coronary Stents by Product Segment - Bare Metal
Stent and Drug Eluting Stent Markets Independently Analyzed
with Annual Sales in US$ Million for years 2007 through 2015
(includes corresponding Graph/Chart) 125
Table 99: Asia-Pacific Recent Past, Current & Future
Analysis for Coronary Stents by Product Segment - Bare Metal
Stent and Drug Eluting Stent Markets Independently Analyzed
with Annual Sales in Thousand Units for years 2007 through
2015 (includes corresponding Graph/Chart) 126
Table 100: Asia-Pacific Historic Review for Coronary Stents
by Product Segment - Bare Metal and Drug Eluting Stent
Markets Independently Analyzed with Annual Sales in US$
Million for years 2001 through 2006 (includes corresponding
Graph/Chart) 126
Table 101: Asia-Pacific Historic Review for Coronary Stents
by Product Segment - Bare Metal and Drug Eluting Stent
Markets Independently Analyzed with Annual Sales in Thousand
Units for years 2001 through 2006 (includes corresponding
Graph/Chart) 127
Table 102: Asia-Pacific 11-Year Perspective for Coronary
Stents by Product Segment - Percentage Breakdown of Dollar
Sales for Bare Metal Stents and Drug Eluting Stents Markets
for years 2005, 2010 & 2015 127
Table 103: Asia-Pacific 11-Year Perspective for Coronary
Stents by Product Segment - Percentage Breakdown of Unit
Sales for Bare Metal Stents and Drug Eluting Stents Markets
for years 2005, 2010 & 2015 127
18. REST OF WORLD 128
A.Market Analysis 128
Brazil - Low Penetration of DES 128
South Africa - Leading Players 128
Table 104: Leading Players in South African Coronary Stent
Market (2006) - Percentage Breakdown by Unit Sales for
Johnson & Johnson, Boston Scientific, Guidant, Abbott,
Sorin, and Others (includes corresponding Graph/Chart) 128
B.Market Analytics 129
Table 105: Rest of World Recent Past, Current & Future
Analysis for Coronary Stents by Product Segment - Bare Metal
Stent and Drug Eluting Stent Markets Independently Analyzed
with Annual Sales in US$ Million for years 2007 through 2015
(includes corresponding Graph/Chart) 129
Table 106: Rest of World Recent Past, Current & Future
Analysis for Coronary Stents by Product Segment - Bare Metal
Stent and Drug Eluting Stent Markets Independently Analyzed
with Annual Sales in Thousand Units for years 2007 through
2015 (includes corresponding Graph/Chart) 129
Table 107: Rest of World Historic Review for Coronary Stents
by Product Segment - Bare Metal and Drug Eluting Stent
Markets Independently Analyzed with Annual Sales in US$
Million for years 2001 through 2006 (includes corresponding
Graph/Chart) 130
Table 108: Rest of World Historic Review for Coronary Stents
by Product Segment - Bare Metal and Drug Eluting Stent
Markets Independently Analyzed with Annual Sales in Thousand
Units for years 2001 through 2006 (includes corresponding
Graph/Chart) 130
Table 109: Rest of World 11-Year Perspective for Coronary
Stents by Product Segment - Percentage Breakdown of Dollar
Sales for Bare Metal Stents and Drug Eluting Stents Markets
for years 2005, 2010 & 2015 131
Table 110: Rest of World 11-Year Perspective for Coronary
Stents by Product Segment - Percentage Breakdown of Unit
Sales for Bare Metal Stents and Drug Eluting Stents Markets
for years 2005, 2010 & 2015 131
COMPETITION
Total Companies Profiled: 52 (including Divisions/Subsidiaries - 59)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 33
Canada 1
Japan 3
Europe 14
France 1
Germany 5
The United Kingdom 1
Italy 1
Spain 1
Rest of Europe 5
Asia-Pacific (Excluding Japan) 4
Africa 2
Middle-East 2
------------------------------------------
To order this report:
Cardiovascular Devices Industry: Global Coronary Stents Industry
Check our Company Profile, SWOT and Revenue Analysis!
CONTACT |
|
Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
Share this article